BPC-157 bladder-pain report
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Lee E, Walker C, Ayadi B. · Alternative therapies in health and medicine
Study record
- Population
12 women, ages 39–76, with interstitial cystitis unresponsive to pentosan polysulfate.
Read source · Full-text reportPatients, p.14- Formulation
Compounded BPC-157, 2 mg/mL; pharmacy unnamed.
Read source · Full-text reportProcedure, p.14- Route
Cystoscopic injections into bladder-wall tissue.
Read source · Full-text reportProcedure, p.14- Dose & frequency
One procedure totaling 10 mg across ten sites. Not a subcutaneous recovery regimen.
Read source · Full-text reportProcedure, p.14- Study design
Uncontrolled retrospective chart review with patient-reported response assessment.
Read source · Full-text reportMethods, p.13; Results, p.14- Duration
Six-week follow-up; most later contacts occurred four to six months after treatment.
Read source · Full-text reportMethods, p.13–14; Results, p.14- Reported findings
Ten reported complete symptom resolution; two reported 80% improvement. All scored 5 on the paper’s response scale.
Read source · Full-text reportResults and Table 1, p.14- Adverse events
No adverse events or postprocedural complications reported; small retrospective ascertainment cannot establish safety.
Read source · Full-text reportResults, p.14- Monitoring
Pelvic examination, urinalysis, cystoscopy, follow-up and symptom questionnaire.
Read source · Full-text reportMethods, p.13; Patients/Results, p.14
What it supports
Describes patient-reported changes after a local procedure.
What it does not establish
No control group or causal efficacy estimate. Follow-up is not a dosing cycle. Not evidence of musculoskeletal repair or KLOW efficacy.
Funding
Patients paid for treatment; authors declared no conflicts (pp.14,16).
Literature search cutoff: 2026-09-08 · Not independently clinically reviewed
Browse study library